DE602007010268D1 - Diagnostikum und therapeutikum gegen bauchspeicheldrüsenkrebs - Google Patents
Diagnostikum und therapeutikum gegen bauchspeicheldrüsenkrebsInfo
- Publication number
- DE602007010268D1 DE602007010268D1 DE602007010268T DE602007010268T DE602007010268D1 DE 602007010268 D1 DE602007010268 D1 DE 602007010268D1 DE 602007010268 T DE602007010268 T DE 602007010268T DE 602007010268 T DE602007010268 T DE 602007010268T DE 602007010268 D1 DE602007010268 D1 DE 602007010268D1
- Authority
- DE
- Germany
- Prior art keywords
- diagnostic
- pancreas cancer
- therapeutic against
- against pancreas
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 3
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006114134 | 2006-04-18 | ||
JP2006291091 | 2006-10-26 | ||
JP2006347544 | 2006-12-25 | ||
PCT/JP2007/000423 WO2007122820A1 (ja) | 2006-04-18 | 2007-04-18 | 膵臓癌の診断薬及び治療薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602007010268D1 true DE602007010268D1 (de) | 2010-12-16 |
Family
ID=38624739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602007010268T Active DE602007010268D1 (de) | 2006-04-18 | 2007-04-18 | Diagnostikum und therapeutikum gegen bauchspeicheldrüsenkrebs |
Country Status (10)
Country | Link |
---|---|
US (2) | US8211630B2 (de) |
EP (1) | EP2009443B1 (de) |
JP (1) | JP5090342B2 (de) |
KR (1) | KR101380057B1 (de) |
CN (1) | CN101460849B (de) |
AT (1) | ATE487139T1 (de) |
AU (1) | AU2007242340B2 (de) |
CA (1) | CA2650699A1 (de) |
DE (1) | DE602007010268D1 (de) |
WO (1) | WO2007122820A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2681899C (en) | 2007-03-27 | 2018-06-19 | Immunovia Ab | Methods for diagnosis of pancreatic adenocarcinoma, and biomarkers and arrays for use in the same |
KR20130036012A (ko) * | 2010-05-07 | 2013-04-09 | 에프. 호프만-라 로슈 아게 | 생체외 세포의 검출을 위한 진단 방법 |
GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003165A2 (en) | 2002-06-28 | 2004-01-08 | Imclone Systems Incorporated | Novel polynucleotide and polypeptide sequences and uses thereof |
US20060241284A1 (en) | 2002-12-13 | 2006-10-26 | Juha Kuja-Panula | Transmembrane protein amigo and uses thereof |
CN1746676A (zh) * | 2004-09-08 | 2006-03-15 | 中国医学科学院肿瘤医院肿瘤研究所 | 一种胰腺癌血清标志分子的检测方法 |
KR20090039748A (ko) * | 2006-07-20 | 2009-04-22 | 노파르티스 아게 | 암의 치료, 진단 또는 검출을 위한 amigo-2 억제제 |
-
2007
- 2007-04-18 CA CA002650699A patent/CA2650699A1/en not_active Abandoned
- 2007-04-18 KR KR1020087023734A patent/KR101380057B1/ko not_active IP Right Cessation
- 2007-04-18 EP EP07737080A patent/EP2009443B1/de active Active
- 2007-04-18 CN CN2007800142299A patent/CN101460849B/zh not_active Expired - Fee Related
- 2007-04-18 WO PCT/JP2007/000423 patent/WO2007122820A1/ja active Application Filing
- 2007-04-18 DE DE602007010268T patent/DE602007010268D1/de active Active
- 2007-04-18 US US12/297,759 patent/US8211630B2/en not_active Expired - Fee Related
- 2007-04-18 AU AU2007242340A patent/AU2007242340B2/en not_active Ceased
- 2007-04-18 AT AT07737080T patent/ATE487139T1/de not_active IP Right Cessation
- 2007-04-18 JP JP2008511970A patent/JP5090342B2/ja not_active Expired - Fee Related
-
2011
- 2011-07-14 US US13/182,492 patent/US8273859B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2009443A4 (de) | 2009-04-22 |
JPWO2007122820A1 (ja) | 2009-09-03 |
WO2007122820A1 (ja) | 2007-11-01 |
ATE487139T1 (de) | 2010-11-15 |
CA2650699A1 (en) | 2007-11-01 |
US8273859B2 (en) | 2012-09-25 |
AU2007242340B2 (en) | 2012-06-28 |
JP5090342B2 (ja) | 2012-12-05 |
CN101460849B (zh) | 2013-02-13 |
EP2009443A1 (de) | 2008-12-31 |
AU2007242340A1 (en) | 2007-11-01 |
EP2009443B1 (de) | 2010-11-03 |
US8211630B2 (en) | 2012-07-03 |
KR101380057B1 (ko) | 2014-04-01 |
US20100316568A1 (en) | 2010-12-16 |
CN101460849A (zh) | 2009-06-17 |
US20110288278A1 (en) | 2011-11-24 |
KR20090008195A (ko) | 2009-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL300936I2 (nl) | Semaglutide | |
NL301089I2 (nl) | imlifidase | |
CY1115871T1 (el) | Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας | |
NL1026089A1 (nl) | Scintillator welke een geïntegreerde collimator heeft en werkwijze voor het vervaardigen daarvan. | |
ATE463254T1 (de) | Antikörper gegen phosphorylcholinkonjugate | |
BRPI0519047A2 (pt) | mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores | |
BRPI0718146A2 (pt) | Dispositivos de infusão e métodos | |
PT2061814E (pt) | Anticorpos e imunoconjugados e suas utilizações | |
ATE484264T1 (de) | Beleuchtete infusionskanüle | |
TW200745161A (en) | Stable antibody formulation | |
HK1125855A1 (en) | Use of oligouronates for treating mucus hyperviscosity | |
DK2109623T3 (da) | Cancerbehandling med anti-IL-1-antistoffer | |
NO20072285L (no) | S-mirtazapin for behandling av hetetokter | |
DK1856070T3 (da) | Nye lægemidler til behandling af luftvejssygdomme | |
CY1110027T1 (el) | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων | |
DE602007010268D1 (de) | Diagnostikum und therapeutikum gegen bauchspeicheldrüsenkrebs | |
IL185653A0 (en) | Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1 | |
CY1115587T1 (el) | Μεθοδος και συνθεση για την θεραπεια παθησης με την μεσολαβηση ενος ληπτη σεροτονινης (sεrοτονιν) | |
TW200740845A (en) | Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue | |
ATE543508T1 (de) | Therapeutische verwendung von gba2 | |
CY1112045T1 (el) | Ενδοαρθρικες φαρμακοτεχνικες μορφες στανοζολολης | |
GT200500033A (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes | |
ITBO20060507A1 (it) | Key' story bookprocedimento di esecuzione del libro senza parole. | |
FR2868424B1 (fr) | Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique | |
BRPI0602549B1 (pt) | gaveta classificadora de medicamentos e procedimento de fabricação de gaveta classificadora de medicamentos. |